Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.

ABSTRACT:

Background

Knowledge on immunity after SARS-CoV-2 infection in patients with multiple sclerosis (pwMS) and the impact of disease-modifying treatment (DMT) is limited.

Objective

To evaluate degree, duration and potential predictors of specific humoral immune response in pwMS with prior COVID-19.

Methods

Anti-SARS-CoV-2 antibody testing was performed in pwMS with PCR-confirmed diagnosis of symptomatic COVID-19 from a nation-wide registry. Predictors of seropositivity were identified by multivariate regression models.

Results

In 125 pwMS (mean age = 42.4 years (SD = 12.3 years), 70% female), anti-SARS-CoV-2 antibodies were detected in 76.0% after a median of 5.2 months from positive PCR. Seropositivity rate was significantly lower in patients on IS-DMT (61.4%,

SUBMITTER: Bsteh G 

PROVIDER: S-EPMC8597187 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature